Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Maternity
  4. Back
  5. Ultrasound
  6. 1st Trimester Screening for Trisomy 21 (T21), Trisomy 18 (T18), Trisomy 13 (T13) in Singleton pregnancies: Nuchal Translucency (NT) Scan (499)
Announcements and latest updates

Right Decision Service newsletter: September 2024

Welcome to the Right Decision Service (RDS) newsletter for September 2024.

1.Business case for permanent provision of the Right Decision Service from April 2025 onwards

This business case has now been endorsed by the HIS Board and will shortly be submitted to Scottish Government.

2. Management of RDS support tickets

To balance increasing demand with available capacity and financial resource, the RDS team and Tactuum are now working together to  implement closer management of support tickets. As a key part of this, we want to ensure clear, timely and consistent communication with yourselves as requesters.  

Editors will now start seeing new messages come through in response to support ticket requests which reflect this tightening up and improvement of our processes.

Key points to note are:

2.1 Issues confirmed by the RDS and Tactuum teams as meeting the critical/urgent and high priority criteria will continue to be prioritised and dealt with immediately.

Critical/urgent issues are defined as:

  1. The Service as a whole is not operational for multiple users. OR
  2. Multiple core functions of the Service are not operational for multiple users.

Example – RDS website outage.

Please remember to email ann.wales3@nhs.scot and his.decisionsupport@nhs.scot with any critical/urgent issues in addition to raising a support ticket.

High priority issues are defined as:

  1. A single core function of the Service is not operational for multiple users. OR:
  2. Multiple non-core functions of the Service are not operational for multiple users.

Example – Build to app not working.

2.2 Support requests that are outwith the warranty period of 12 weeks since the software was originally developed will not be automatically addressed by Tactuum. The RDS team will consider these requests for costed development work and will obtain estimate of effort and cost from Tactuum for priority issues.

2.3 Support tickets for technical issues that are not classified as bugs will not be automatically addressed by Tactuum. The definition of a bug is ‘a defect in the software that is at variance with documented user requirements.’  Issues that are not bugs will also be considered for costed development work.

The majority of issues currently in support tickets fall into category 2 or 3 above, or both.

2.4 Non-urgent requests that require a deployment (i.e a new release of RDS) will normally be factored into the next scheduled release (currently end of Nov 2024 and end of Feb 2025) unless by special agreement with the RDS team.

Please note that we plan to move in the new year to a new system whereby requests all come to an RDS support portal in the first instance and are triaged from there to Tactuum when appropriate.

We will be organising a webinar in a few weeks’ time to take you through the details of the current support processes and criteria.

3. Next scheduled deployment.

The next scheduled RDS deployment will take place at the end of November 2024.  We are reviewing all outstanding support tickets and feature requests along with estimates of effort and cost to determine which items will be included in this deployment.

We will update you on this in the next newsletter and in the planned webinar about support ticket processes.

4. Contingency arrangements for RDS

Many thanks to those of you who attended our recent webinar on the contingency arrangements being put in place to prevent future RDS outages as far as possible and minimise impact if they do occur.  Please contact ann.wales3@nhs.scot if you would like a copy of the slides from this session.

5. Transfer of CKP pathways to RDS

The NES clinical knowledge pathway (CKP) publisher is now retired and the majority of pathways supported by this tool have been transferred to the RDS. Examples include:

NHS Lothian musculoskeletal pathways

NHS Fife rehabilitation musculoskeletal pathways

NHS Tayside paediatric pathways

6. Other new RDS toolkits

Include:

Focus on frailty (from HIS Frailty improvement programme)

NHS GGC Money advice and support

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

To go live imminently:

  • Focus on dementia
  • NHS Lothian infectious diseases toolkit
  • Dumfries and Galloway Adult Support and Protection procedures
  • SIGN guideline – Prevention and remission of type 2 diabetes

 

7. Evaluation projects

We have recently analysed the results of a survey of users of the Scottish Palliative Care Guidelines toolkit.  Key findings from 61 respondents include:

  • Most respondents (64%) are frequent users of the toolkit, using it either daily or weekly. A further 25% use it once or twice per month.
  • 5% of respondents use the toolkit to deliver direct patient care and 82% use it for learning
  • Impact on practice and decision-making was rated as very high, with 80% of respondents rating these at a 4-5 on a 5 point scale.
  • Impact on time saving was also high, with 74% of respondents rating it from 3-5.
  • 74% also reported that the toolkit improved their knowledge and skills, rating these at 4-5 on the Likert scale

Key strengths identified included:

  • The information is useful, succinct, and easy to understand (31%).
  • Coverage is comprehensive (15%)
  • All information is readily accessible in one place and users value the offline access via mobile app (15%)
  • Information is reliable, evidence-based and up to date (13%)

Users highlighted key areas for improvement in terms of navigation and search functionality. The survey was very valuable in enabling us to uncover the specific issues affecting the user experience. Many of these can be addressed through content management approaches. The issues identified with search results echo other user feedback, and we are costing improvements with a view to implementation in the next RDS deployment.

8.RDS High risk prescribing (polypharmacy) decision support embedded in Vision and EMIS primary care E H R systems

This decision support software, sponsored by Scottish Government Effective Prescribing and Therapeutics Division,  is now available for all primary care clinicians across NHS Tayside. Board-wide implementation is also planned for NHS Lothian, and NHS GGC, NHS Ayrshire and Arran and NHS Dumfries and Galloway have initial pilots in progress. The University of Dundee has been commissioned to evaluate impact of this decision support software on prescribing practice.

9. Video tutorials for RDS editors

Ten bite-size (5 mins or less) video tutorials for RDS editors are now available in the “Resources for providers of RDS tools” section of the RDS.  These cover core functionality including Save and preview, content page and media management, password management and much more.

10. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Wednesday 23rd October 4-5 pm
  • Tuesday 29th October 11 am -12 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

 

1st Trimester Screening for Trisomy 21 (T21), Trisomy 18 (T18), Trisomy 13 (T13) in Singleton pregnancies: Nuchal Translucency (NT) Scan (499)

Warning

Please report any inaccuracies or issues with this guideline using our online form

Appointments for a dating scan including 1st trimester screening for Down’s, Edwards’ and Patau’s Syndrome (NT measurements) should be no less than 25 minutes. This should include time to get “on and off the couch”, time to perform the ultrasound examination and time to complete the report.

All Sonographers performing NT measurements must be appropriately trained and accredited and their results subjected to rigorous audit and performance management. To assure continuing satisfactory performance each Sonographer must perform a minimum of 25 nuchal translucency measurements every 6 months and have DQASS ‘Green’ or ‘Amber’ flag status.

The ultrasound equipment used must meet NSC FASP specifications. It should have a cineloop function and calliper precision to one decimal point i.e. 0.1mm. Operators should be aware of and adhere to BMUS guidelines for safe use of ultrasound including exposure times.

The screening period is between 11+2 to 14+1 weeks gestation. The scan will be targeted at a gestation of approx 12 weeks. The scan can be performed by the transabdominal or transvaginal route.

Consent

Sonographers must ensure formal consent has been obtained. Check the details of the booking on the ‘antenatal assessment’ tab on Badger net under ‘screening and scans offered/accepted or declined'.

Women can chose to have screening for T21 syndrome only or to have screening for T21, T18 & T13. It is not possible to have screening for T18 and/or T13 without screening for T21.

Prior to beginning scan, give a brief explanation of the scan, including limitations and obtain verbal consent to continue.

If consent for 1st trimester screening is not obtained a “dating” scan only should be performed. The Sonographer should also advise that if an increased NT ≥ 3.5mm is detected, this can be indicative of a structural abnormality and would require referral to a Medical Sonographer.

The Ultrasound Examination

Where both dating and 1st trimester screening are requested and the CRL is between 45.0 and 84.0mm, the pregnancy should be dated using the CRL measurement.

Criteria for measurement of the fetal crown rump length (CRL) as part of the combined 1st trimester screening programme

The CRL range should be between 45.0 and 84.0 mm.

The magnification of the fetus should be as large as possible clearly demonstrating the entire crown-rump length.

A midline sagittal section of the whole fetus should be obtained with the fetus horizontal on the screen, either supine or prone. The fetus should be in a neutral position with fluid visible between the fetal chin and chest, neither hyper extended nor flexed.

The best of three measurements should be taken. Linear callipers should be used to measure the maximum un-flexed length. Intersection of the callipers (+) should be placed on the outer margin of the skin borders of the CRL. Two images of the measured CRL must be retained, one for the patient record and one for audit purposes.

If the CRL is < 45.0mm re-appoint the patient within the 11+2 – 14+1 weeks screening window.

If the CRL is > 84.0mm arrange appointment for 2nd trimester biochemistry screening and date pregnancy using Head Circumference (HC).

The NT Measurement

The NT measurement should only be performed if a CRL measurement, which meets the recommended NHS FASP criteria for CRL has been obtained.

Criteria for measurement of the fetal nuchal translucency (NT) measurement

A midline sagittal section of the fetus should be obtained. The fetus should be horizontal on the screen, either supine or prone.

Care must be taken to distinguish between fetal skin and amnion. The fetus should be in a neutral position.

The image should be magnified, such that only the fetal head and upper thorax occupy the whole screen. In magnifying the image (pre- or post-zoom) it is important to turn down the gain.

The widest part of the translucency must always be measured. Measurements should be taken with the horizontal lines of the callipers placed ON the lines that define the NT thickness.

During the scan more than one measurement must be taken and the maximum one which meets all the criteria should be recorded. Two images of this measured NT should be retained, one for the patient record, one for audit purposes.

If the NT measurement is ≥ 3.5mm, perform combined screening test and follow pathway for raised nuchal translucency (NT) ≥ 3.5mm

Too early/late/unable to obtain measurements

Too Early: CRL measurement <45.0mm – re-appoint at appropriate gestation.

Too late: CRL measurement >84.0mm – arrange appointment for 2nd trimester biochemistry (≥ 15+0 weeks) screening and date pregnancy using Head Circumference (HC).

Unable to obtain measurements – offer a 2nd attempt. This second attempt at screening should be on the same day.

If unable to obtain measurements after two attempts, explain limitations of scan and record on report. Arrange 2nd trimester dating scan to coincide with biochemistry appointment.

Ultrasound Images

One set of paired CRL and NT images to be inserted into brown image envelope in patient notes, one set to be kept aside for audit purposes.

Ultrasound Report

The Ultrasound report should be documented on Badgernet under ‘Key Notes – New Ultrasound Note’. Ensure all appropriate fields are filled including the authorization box (your digital signature) for the report to be valid.

If unable to obtain NT measurements indicate reason for failed attempt i.e. poor views due to fetal position. If patient to be re-appointed for 2nd trimester screening enter suggested date.  

Medical Genetics Form (Appendix A)

Attach a patient label, with name, address, DOB and CHI number to the Medical Genetics First Trimester Combined Ultrasound and Biochemical (CUB) Screening form.

Enter the following data:

  • Hospital
  • Consultant
  • Maternal Weight
  • Number of Fetuses
  • Chorionicity if multiple pregnancy
  • Maternal Family Origin

Indicate YES or NO for the following categories:

  • Screening required – Down’s Syndrome T21
  • Screening required – Edwards’ Syndrome T18 and Patau’s Syndrome T13
  • Current Smoker
  • Previous Trisomy Pregnancy
  • IDDM

Complete the Ultrasound Details section;

  • Date of scan
  • Estimated date of delivery
  • CRL (mm)
  • NT (mm)
  • Ultrasonographer code

If assisted conception pregnancy, record all relevant details in the Assisted Conception section

“Date of sample” and “Sample taken by” fields to be entered by the Midwife/HCSW who performs the venipuncture.

Medical Genetics form to be passed to the Midwife/HCSW for completion and sent together with the biochemistry sample to Medical Genetics Labs.

Appendix A - Medical Genetics Form

Medical Genetics, First Trimester Combined Ultrasound and Biochemical (CUB) Screening Form.

 

Editorial Information

Last reviewed: 03/05/2024

Next review date: 04/05/2028

Author(s): Donna Bean.

Version: 3

Co-Author(s): Alan Mathers.

Approved By: Maternity Governance Group

Document Id: 499